webinars
This talk explores the expanding role of flow cytometry in CAR-T and cellular therapy bioanalysis—from its origins supporting the earliest autologous CAR-T clinical trials to its expanding role in next-generation in vivo CAR therapies. We will trace how flow cytometry methods have matured alongside the CAR landscape, becoming a primary platform…
Blogs
Chimeric Antigen Receptor (CAR) therapies represent a maturing class of therapeutics with both significant clinical impact and significant analytical complexity. Unlike small molecules or traditional biologics, CAR‑T cells are living drugs with dynamic behavior that introduces a level of complexity that cannot be measured by just a single…
Blogs
CyTOF and spectral flow cytometry are widely used technologies for high-dimensional single cell profiling of immune cells. Both technologies enable multiparameter single-cell analysis, but they differ significantly in how data are generated, how quickly studies can be executed, and how flexible an assay can be tailored for a…
Blogs
Evolving CAR Therapies and the Growing Need for Robust PK/PD Monitoring Chimeric Antigen Receptor (CAR) based therapies are a growing and continuing focus in oncology and autoimmune therapeutic development. They utilize either self (autologous) or donor-derived (allogenic) T cells that are genetically engineered to target and kill cancerous or…
Blogs
Cell-based immunotherapies like Chimeric Antigen Receptor (CAR)-T cell therapy have been transforming the treatment of hematologic malignancies for more than a decade. Several groundbreaking studies (1) have led to a growing interest in applying these cell-based therapies to other T and B cell-mediated diseases. One emerging application of CARs…